Market Overview

Piper Jaffray Initiates Coverage on Cytokinetics, Incorporated at Overweight, Announces $4.00 PT

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for CYTK

DateFirmActionFromTo
Nov 2014MLV & Co.UpgradesHoldBuy
May 2014Leerink SwannMaintainsOutperform
Apr 2014Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for CYTK
View the Latest Analyst Ratings

Posted-In: News Analyst Ratings

 

Related Articles (CYTK)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional